ASH 2022 | Blast-phase MPNs: a major unmet need in the field
In this video, Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, outlines the optimal treatment approach for blast-phase myeloproliferative neoplasms (BP-MPNs). Dr Kuykendall begins by highlighting the challenges with treating patients with BP-MPNs, and then goes on to discuss the need to further investigate novel, targeted treatment approaches. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Protagonist: Other: Research Support; Imago Biosciences: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria, Speakers Bureau; Blueprint Medicines Corporation: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Abbvie: Consultancy, Honoraria, Speakers Bureau; GSK – Sierra Oncology: Consultancy, Honoraria, Other: Research Support, Speakers Bureau; Prelude Pharmaceuticals: Other: Research Support; BMS: Consultancy, Honoraria, Other: Research Support, Speakers Bureau; Morphosys: Other: Research Support; Pharmaessentia: Consultancy, Honoraria, Speakers Bureau; CTI Biopharma: Consultancy, Honoraria, Speakers Bureau.
